By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Rosetta Genomics said in a regulatory document that revenues for full-year 2011 dropped 63 percent year over year.

In its Form 10-K filed with the US Securities and Exchange Commission today, the Israel-based molecular diagnostics firm said that revenues for 2011 came in at $103,000, down from $279,000 in 2010, due primarily to its former distributor in the US ending sales of Rosetta products in late 2010.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: association between genome-wide homozygosity and traits like height and cognitive ability, improved CRISPR-Cas9 editing, and more.

A survey examines how age, political leanings, and more influence how Americans view certain scientific topics, the Associated Press reports.

A researcher who pleaded guilty to making false statements in research reports has been sentenced to four and a half years in prison and must pay $7.2 million back to the NIH.

The BabySeq project to study the risks and benefits of sequencing newborns is underway.